Human FcGR2B Recombinant Cell Line, CHO-K1 (CAT#: IOC-LX108)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant FcGR2B-CHO K1 cell line stably expressing full length human FcGR2B (isoform 1, GenBank Accession Number NM_004001.4). Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

•Screen for activators or inhibitors of antibody-mediated signaling by coculturing with the FcGR2B CHO K1 cells.
•Characterize the agonist activity of antibodies by crosslinking to the FcGR2B receptor.

Human

CHO-K1

FcGR2B

Fc Gamma Receptor 2B (FcGR2B, FcγRIIB), also known as CD32B, is a "low affinity" receptor for Immunoglobulin G (IgG). FcGR2B is involved in the phagocytosis of immune complexes and in the regulation of antibody production by B-cells. Mutations in the gene encoding FcGR2B have been linked to systemic lupus erythematosus (SLE). FcGR2B is the predominant Fc receptor present on B cells, and high expression of FcγRIIB negatively regulates mAb-mediated immunotherapy. Therefore, FcGR2B is an important immunotherapy target, both directly for B-cell malignancies and in combination with clinically relevant therapeutic mAbs to overcome FcGR2B-mediated resistance.